[Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus].
The cardiovascular mortality rate increases worldwide. The most important factor of the lethal outcome is the type 2 diabetes mellitus. For the treatment of this disease there are several preparations, thus the drugs increasing insulin secretion (insulin secretagogues), the compounds enhancing insulin effect (insulin sensitisers) and glucose absorption inhibitors. These can be applied both in monotherapy and in combination mode. Among the drugs approved the combination of glimepiride and rosiglitazone have got a great importance in routine use. Glimepiride stimulates the beta-cell secretion and leads to reduction of blood glucose values, rosiglitazone stimulates peroxisome proliferator-activated receptor-gamma and improves insulin resistance, at the vascular and metabolically active cells. The combination of glimepiride and rosiglitazone is generally well tolerated and their use of a fixed combination may lead to improved adherence of the patients to their therapy.
Fehér
János
J
Semmelweis Egyetem, Altalános Orvostudományi Kar, II. Belgyógyászati Klinika, Budapest. feher@bel2@sote.hu
Lengyel
Gabriella
G
D000284:Administration, Oral; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007333:Insulin Resistance; D047495:PPAR gamma / Q000187:drug effects; D000077154:Rosiglitazone; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D000077154:Rosiglitazone; C057619:glimepiride